ES2187668T3 - Formulacion de oxido de 1,2,4-benzotriazina en capsulas de gel oral es. - Google Patents

Formulacion de oxido de 1,2,4-benzotriazina en capsulas de gel oral es.

Info

Publication number
ES2187668T3
ES2187668T3 ES96928255T ES96928255T ES2187668T3 ES 2187668 T3 ES2187668 T3 ES 2187668T3 ES 96928255 T ES96928255 T ES 96928255T ES 96928255 T ES96928255 T ES 96928255T ES 2187668 T3 ES2187668 T3 ES 2187668T3
Authority
ES
Spain
Prior art keywords
formulation
gel capsules
oral gel
benzotriazine oxide
benzotriazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96928255T
Other languages
English (en)
Inventor
Stephen Brown
Ross Blundell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Synthelabo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo Inc filed Critical Sanofi Synthelabo Inc
Application granted granted Critical
Publication of ES2187668T3 publication Critical patent/ES2187668T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN CAPSULAS DE GELATINA BLANDA CONTRA TUMORES CANCEROSOS QUE COMPRENDEN OXIDO DE 1,2,4 - BENZOTRIAZINA Y UN EXCIPIENTE OLEOSO SELECCIONADO DE UN GRUPO QUE CONSISTE EN ACEITE DE SOJA Y ACEITE DE COCO FRACCIONADO.
ES96928255T 1995-09-12 1996-08-21 Formulacion de oxido de 1,2,4-benzotriazina en capsulas de gel oral es. Expired - Lifetime ES2187668T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/527,233 US5597582A (en) 1995-09-12 1995-09-12 Oral gel capsule formulation of 1,2,4-benzotriazine oxides

Publications (1)

Publication Number Publication Date
ES2187668T3 true ES2187668T3 (es) 2003-06-16

Family

ID=24100665

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96928255T Expired - Lifetime ES2187668T3 (es) 1995-09-12 1996-08-21 Formulacion de oxido de 1,2,4-benzotriazina en capsulas de gel oral es.

Country Status (19)

Country Link
US (1) US5597582A (es)
EP (1) EP0868174B1 (es)
JP (1) JPH11513365A (es)
KR (1) KR100475388B1 (es)
CN (1) CN1080113C (es)
AT (1) ATE227982T1 (es)
AU (1) AU702550B2 (es)
CA (1) CA2231545C (es)
CZ (1) CZ289733B6 (es)
DE (1) DE69624935T2 (es)
DK (1) DK0868174T3 (es)
ES (1) ES2187668T3 (es)
HK (1) HK1016889A1 (es)
HU (1) HUP9802605A3 (es)
MX (1) MX9801930A (es)
NO (1) NO320019B1 (es)
NZ (1) NZ315964A (es)
PT (1) PT868174E (es)
WO (1) WO1997009968A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
PT2275098E (pt) * 2004-05-04 2012-08-29 Hormos Medical Ltd Novas formulações orais de ospemifeno
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
CN104705772B (zh) * 2015-01-28 2016-09-14 汤臣倍健股份有限公司 一种改善软胶囊漏油的生产工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60239418A (ja) * 1984-05-15 1985-11-28 Nippon Kayaku Co Ltd エトポシド軟カプセル製剤
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
US5637085A (en) * 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site

Also Published As

Publication number Publication date
DE69624935T2 (de) 2003-03-27
NO981042L (no) 1998-03-10
EP0868174A4 (es) 1998-10-07
CZ289733B6 (cs) 2002-03-13
NO320019B1 (no) 2005-10-10
PT868174E (pt) 2003-04-30
CN1200669A (zh) 1998-12-02
HK1016889A1 (en) 1999-11-12
HUP9802605A2 (hu) 1999-04-28
KR100475388B1 (ko) 2005-08-05
JPH11513365A (ja) 1999-11-16
US5597582A (en) 1997-01-28
CN1080113C (zh) 2002-03-06
HUP9802605A3 (en) 2000-02-28
CA2231545A1 (en) 1997-03-20
CA2231545C (en) 2008-07-15
DK0868174T3 (da) 2003-03-17
AU6780096A (en) 1997-04-01
KR19990044573A (ko) 1999-06-25
EP0868174B1 (en) 2002-11-20
ATE227982T1 (de) 2002-12-15
EP0868174A1 (en) 1998-10-07
DE69624935D1 (de) 2003-01-02
NZ315964A (en) 1999-03-29
NO981042D0 (no) 1998-03-10
MX9801930A (es) 1998-10-31
AU702550B2 (en) 1999-02-25
WO1997009968A1 (en) 1997-03-20
CZ64498A3 (cs) 1998-08-12

Similar Documents

Publication Publication Date Title
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
MX9306499A (es) Composiciones farmaceuticas que contienen una anfetamina.
ATE302614T1 (de) Kosmetische oder dermo-pharmazeutische zusammensetzung in form von hydrophoben perlen und herstellungsverfahren
BR9815589A (pt) Composições viscosas aquosas, lìmpidas ou não, para à fabricação de cápsulas macias ou duras, e processo de fabricação de pelìcilas para tais cápsulas
BR9506820A (pt) Derivados de 4-amino de ácido micofenólico
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
ATE62392T1 (de) Shampoo-zusammensetzungen und verfahren.
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
DE69629989D1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
ES2156375T3 (es) Composicion de champu acondicionador.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
MX9401294A (es) Derivados de azolona sustituida
PT839149E (pt) Derivados da galantamina processo de sua preparacao sua aplicacao como medicamento e as composicoes farmaceuticas que as contem
ATE131722T1 (de) Verfahren zur inaktivierung von umhüllten viren und sperma
ES2187668T3 (es) Formulacion de oxido de 1,2,4-benzotriazina en capsulas de gel oral es.
DE3767584D1 (de) Gemischte lanthanium-magnesium-aluminate und die aluminate benutzende laser.
FI850304A0 (fi) Indolofenathridiner.
DE3584331D1 (de) Pharmazeutische zusammensetzung und verfahren um eine antiallergische wirkung hervorzurufen.
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
LV12149A (lv) 5-Aizvietoti mikofenolskabes 4-aminoatvasinajumi
FR2753707B1 (fr) Complexes nucleopeptidiques, compositions cosmetologiques et pharmaceutiques les contenant et utilisations
FR2652742B1 (fr) Compositions anallergiques cosmetiques et dermo-pharmaceutiques.
ATE285745T1 (de) Lippenstifte, deren ölanteile nicht ausschwitzen
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.